U.S. Markets closed

Ex-Dividend Alert: Johnson & Johnson Boosted its Dividend by 7.1%; Will Trade Ex-Dividend on May 25, 2018

LONDON, UK / ACCESSWIRE / May 24, 2018 / Active-Investors has a free review on Johnson & Johnson (NYSE: JNJ) following the Company's announcement that it will begin trading ex-dividend on May 25, 2018. To capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date that is by latest at the end of the trading session on May 24, 2018. Active-Investors has initiated due-diligence on this dividend stock. Register with us for more free research including the one on JNJ:


If your portfolio includes dividend stocks, you have come to the right place for timely information. All you need to do is sign up for your free membership at:


Dividend Declared

On April 26, 2018, Johnson & Johnson announced that its Board of Directors has declared a 7.1% increase in the quarterly dividend rate from $0.84 per share to $0.90 per share.

"In recognition of our 2017 results, strong financial position and confidence in the future of Johnson & Johnson, the Board has voted to increase the quarterly dividend for the 56th consecutive year," said Alex Gorsky, Chairman and Chief Executive Officer of the company.

The next quarterly dividend is payable on June 12, 2018, to shareholders of record as of the close of business on May 29, 2018.

Johnson & Johnson's indicated dividend represents a yield of 2.91%, which is more than four times higher than to the average dividend yield of 0.68% for the Healthcare sector. The Company has raised its dividend for fifty-six consecutive years.

Dividend Insights

Johnson & Johnson has a dividend payout ratio of 44.3%, which denotes that the Company spends approximately $0.44 for dividend distribution out of every $1.00 earned. The dividend payout ratio reflects how much amount a company is returning to shareholders versus how much money it is keeping on hand to reinvest in growth, to pay off debt, and/or to add to its cash reserves.

According to analysts' estimates, Johnson & Johnson is forecasted to report earnings of $8.58 per share for the next year, which is more than double compared to the Company's annualized dividend of $3.60 per share.

As of April 01, 2018, Johnson & Johnson's cash and cash equivalents totaled $14.64 billion compared to $17.82 billion as on December 31, 2017. For the three months ended April 01, 2018, the Company's net cash flow from operating activities was $3.61 billion compared to $2.91 billion for the year ago same period. The Company's strong financial position indicates its ability to absorb any fluctuations in earnings and cash flow and to sustain the dividend distribution for a long period.

Recent Development for Johnson & Johnson

On May 14, 2018, DePuy Synthes Products, Inc., part of the Johnson & Johnson Medical Devices companies, announced that it has signed a definitive agreement to acquire the assets of Medical Enterprises Distribution, LLC, a privately held developer of surgical impactor technology, including the automated ME1000™ Surgical Impactor for use in hip replacement.

The transaction is expected to close in the second quarter of 2018. The closing is subject to antitrust clearance and other customary closing conditions. Financial terms of the acquisition are not being disclosed.

The ME1000 is a battery-powered device that automates bone preparation, implant assembly, and positioning in Total Hip Arthroplasty (THA). It is designed to replace the handheld mallet used in the procedure, leading to more consistent clinical outcomes while also helping to reduce surgeon fatigue as well as the potential for work-related injuries that can arise from mallet use.

Stock Performance Snapshot

May 23, 2018 - At Wednesday's closing bell, Johnson & Johnson's stock slightly rose 0.44%, ending the trading session at $123.45.

Volume traded for the day: 4.93 million shares.

After yesterday's close, Johnson & Johnson's market cap was at $331.12 billion.

Price to Earnings (P/E) ratio was at 22.77.

The stock has a dividend yield of 2.72%.

The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Major industry. This sector was up 0.2% at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors